Anti-PD-L1 Antibody

Price:
Size:
Number:

Anti-PD-L1 Antibody (Rabbit Polyclonal antibody) General Information

Product name
Anti-PD-L1 Antibody
Validated applications
ELISA
Species reactivity
Reacts with: Human
Specificity
Human PD-L1
Immunogen
Recombinant Human B7-H1 / CD274 / PD-L1 protein (Catalog#10084-H08H)
Preparation
Produced in rabbits immunized with purified, recombinant Human B7-H1 / CD274 / PD-L1 (rh B7-H1; Catalog#10084-H08H; NP_054862.1; Met 1-Thr 239). B7-H1 specific IgG was purified by Human B7-H1 affinity chromatography.
Source
Polyclonal Rabbit IgG
Purification
Protein A & Antigen Affinity
Formulation
0.2 μm filtered solution in PBS
Conjugate
Unconjugated
Form
Liquid
Shipping
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Storage
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles.

Anti-PD-L1 Antibody (Rabbit Polyclonal antibody) Validated Applications

Application Dilution
ELISA 1:5000-1:10000
Please Note: Optimal concentrations/dilutions should be determined by the end user.

Anti-PD-L1 Antibody: Alternative Names

Anti-B7-H Antibody; Anti-B7-H1 Antibody; Anti-B7H1 Antibody; Anti-PD-L1 Antibody; Anti-PDCD1L1 Antibody; Anti-PDCD1LG1 Antibody; Anti-PDL1 Antibody

PD-L1 Background Information

Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain, and together with PD-L2, are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.
Full Name
CD274 molecule
References
  • Iwai Y, et al. (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 99(19): 12293-7.
  • Ghebeh H, et al. (2006) The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 8(3): 190-8.
  • Salih HR, et al. (2006) The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans. Exp Hematol. 34(7): 888-94.
  • Wilcox RA, et al. (2009) B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood. 114(10): 2149-58.
  • Ruggiero A, et al. (2009) Crystal structure of PD-L1, a ribosome inactivating protein from Phytolacca dioica L. leaves with the property to induce DNA cleavage. Biopolymers. 91(12): 1135-42.

Standard Antibody Development Service

Rabbit MAb

Mouse MAb

Rabbit PAb

Fast Antibody Development Service

Mouse MAb

Rabbit PAb

Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait